Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
— First subcutaneous, once-monthly octreotide for treatment of acromegaly — For convenient self-administration with a pre-filled autoinjector pen Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin […]